FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986289133> ?p ?o ?g. }

• W1986289133 endingPage "115" @default.
• W1986289133 startingPage "115" @default.
• W1986289133 abstract "Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide Lawrence KleinbergDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Oncology Center Johns Hopkins University, Baltimore, MD, USAAbstract: The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel®) polymer implant wafer is a biodegradable compound containing 3.85% carmustine which slowly degrades to release carmustine and protects it from exposure to water with resultant hydrolysis until the time of release. The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events. Based on these trials and other supporting data, US and European regulatory authorities granted approval for its use in recurrent and newly diagnosed malignant glioma, and it remains the only approved local treatment. The preclinical and clinical data suggest that it is optimally utilized primarily in the proportion of patients who may have total or near total removal of gross tumor. The aim of this work was to review the evidence for the use of carmustine implants in the management of malignant astrocytoma (World Health Organization grades III and IV), including newly diagnosed and recurrent disease, especially in the setting of a standard of care that has changed since the randomized trials were completed. Therapy has evolved such that patients now generally receive temozolomide chemotherapy during and after radiotherapy treatment. For patients undergoing repeat resection for malignant glioma, a randomized, blinded, placebo-controlled trial demonstrated a median survival for 110 patients who received carmustine polymers of 31 weeks compared with 23 weeks for 122 patients who only received placebo polymers. The benefit achieved statistical significance only on analysis adjusting for prognostic factors rather than for the randomized groups as a whole (hazard ratio = 0.67, P = 0.006). A blinded, placebo-controlled trial has also been performed for carmustine implant placement in newly diagnosed patients prior to standard radiotherapy. Median survival was improved from 11.6 to 13.9 months (P = 0.03), with a 29% reduction in the risk of death. When patients with glioblastoma multiforme alone were analyzed, the median survival improved from 11.4 to 13.5 months, but this improvement was not statistically significant. When a Cox&#39;s proportional hazard model was utilized to account for other potential prognostic factors, there was a significant 31% reduction in the risk of death (P = 0.04) in this subgroup. Data from other small reports support these results and confirm that the incidence of adverse events does not appear to be increased meaningfully. Given the poor prognosis without possibility of cure, these benefits from a treatment with a favorable safety profile were considered meaningful. There is randomized evidence to support the use of carmustine wafers placed during resection of recurrent disease. Therefore, although there is limited specific evidence, this treatment is likely to be efficacious in an environment when nearly all patients receive temozolomide as part of initial management. Given that half of the patients in the randomized trial assessing the value of carmustine implants in recurrent disease had received prior chemotherapy, it is likely that this remains a valuable treatment at the time of repeat resection, even after temozolomide. There are data from multiple reports to support safety. Although there is randomized evidence to support the use of this therapy in newly diagnosed patients who will receive radiotherapy alone, it is now standard to administer both adjuvant temozolomide and radiotherapy. There are survival outcome reports for small cohorts of patients receiving temozolomide with radiotherapy, but this information is not sufficient to support firm recommendations. Based on the rationale and evidence of safety, this approach appears to be a reasonable option as more information is acquired. Available data support the safety of using carmustine wafers in this circumstance, although special attention to surgical guidelines for implanting the wafers is warranted.Keywords: carmustine, Polifeprosan 20, malignant glioma" @default.
• W1986289133 created "2016-06-24" @default.
• W1986289133 creator A5033231728 @default.
• W1986289133 date "2012-10-01" @default.
• W1986289133 modified "2023-09-25" @default.
• W1986289133 title "Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide" @default.
• W1986289133 cites W1516518029 @default.
• W1986289133 cites W1523300071 @default.
• W1986289133 cites W1566345389 @default.
• W1986289133 cites W1570195799 @default.
• W1986289133 cites W1661054359 @default.
• W1986289133 cites W1796022876 @default.
• W1986289133 cites W1900715992 @default.
• W1986289133 cites W1921275294 @default.
• W1986289133 cites W1965642226 @default.
• W1986289133 cites W1966359376 @default.
• W1986289133 cites W1971964492 @default.
• W1986289133 cites W1973087709 @default.
• W1986289133 cites W1977460228 @default.
• W1986289133 cites W1979368164 @default.
• W1986289133 cites W1986674180 @default.
• W1986289133 cites W1987615424 @default.
• W1986289133 cites W1989564923 @default.
• W1986289133 cites W1991946819 @default.
• W1986289133 cites W1992248393 @default.
• W1986289133 cites W1996335306 @default.
• W1986289133 cites W1999641458 @default.
• W1986289133 cites W2005873134 @default.
• W1986289133 cites W2013925475 @default.
• W1986289133 cites W2016663997 @default.
• W1986289133 cites W2017892759 @default.
• W1986289133 cites W2018878216 @default.
• W1986289133 cites W2024024932 @default.
• W1986289133 cites W2024800676 @default.
• W1986289133 cites W2025753978 @default.
• W1986289133 cites W2026332644 @default.
• W1986289133 cites W2028365176 @default.
• W1986289133 cites W2029485040 @default.
• W1986289133 cites W2032090704 @default.
• W1986289133 cites W2033329981 @default.
• W1986289133 cites W2034123092 @default.
• W1986289133 cites W2036560693 @default.
• W1986289133 cites W2042007311 @default.
• W1986289133 cites W2042562804 @default.
• W1986289133 cites W2047287811 @default.
• W1986289133 cites W2052225969 @default.
• W1986289133 cites W205461530 @default.
• W1986289133 cites W2056730157 @default.
• W1986289133 cites W2060187394 @default.
• W1986289133 cites W2063538683 @default.
• W1986289133 cites W2073256642 @default.
• W1986289133 cites W2079305775 @default.
• W1986289133 cites W2080218754 @default.
• W1986289133 cites W2085612880 @default.
• W1986289133 cites W2089500240 @default.
• W1986289133 cites W2090432199 @default.
• W1986289133 cites W2096287682 @default.
• W1986289133 cites W2100567246 @default.
• W1986289133 cites W2110339758 @default.
• W1986289133 cites W2111726732 @default.
• W1986289133 cites W2113012900 @default.
• W1986289133 cites W2117795295 @default.
• W1986289133 cites W2118565356 @default.
• W1986289133 cites W2120919579 @default.
• W1986289133 cites W2128635779 @default.
• W1986289133 cites W2129983423 @default.
• W1986289133 cites W2134680580 @default.
• W1986289133 cites W2149145595 @default.
• W1986289133 cites W2151264866 @default.
• W1986289133 cites W2158681922 @default.
• W1986289133 cites W2159753548 @default.
• W1986289133 cites W2164938540 @default.
• W1986289133 cites W2171186002 @default.
• W1986289133 cites W2224998281 @default.
• W1986289133 cites W2409258363 @default.
• W1986289133 cites W2414169881 @default.
• W1986289133 cites W54382320 @default.
• W1986289133 cites W67670358 @default.
• W1986289133 cites W74845946 @default.
• W1986289133 doi "https://doi.org/10.2147/ce.s23244" @default.
• W1986289133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3484478" @default.
• W1986289133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23118709" @default.
• W1986289133 hasPublicationYear "2012" @default.
• W1986289133 type Work @default.
• W1986289133 sameAs 1986289133 @default.
• W1986289133 citedByCount "16" @default.
• W1986289133 countsByYear W19862891332014 @default.
• W1986289133 countsByYear W19862891332015 @default.
• W1986289133 countsByYear W19862891332016 @default.
• W1986289133 countsByYear W19862891332018 @default.
• W1986289133 countsByYear W19862891332020 @default.
• W1986289133 countsByYear W19862891332022 @default.
• W1986289133 countsByYear W19862891332023 @default.
• W1986289133 crossrefType "journal-article" @default.
• W1986289133 hasAuthorship W1986289133A5033231728 @default.
• W1986289133 hasBestOaLocation W19862891331 @default.
• W1986289133 hasConcept C126322002 @default.
• W1986289133 hasConcept C141071460 @default.

• next